PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Evidence indicates that Ipomoea batatas is effective in the treatment of type 2 diabetes, with phenolic acids, flavonols, flavanones, and anthocyanidins contributing to anti-diabetic activity [PMID: 37509903].
Promising results have been witnessed in the usage of I. batatas in treating hyperglycemic and dyslipidemic conditions [PMID: 34639164].
Purple sweet potato leaf extract (PSPLE) significantly reduced lipid accumulation and triglyceride levels in human bone marrow-derived mesenchymal stem cells [PMID: 35034358].
Evidence summary
PubMed sources
- 1.PMID: 35407143 (2022) — Sweet Potato (Ipomoea batatas L.) Phenotypes: From Agroindustry to Health Effects. · Foods (Basel, Switzerland)
- 2.PMID: 24921903 (2014) — Sweet potato (Ipomoea batatas [L.] Lam)--a valuable medicinal food: a review. · Journal of medicinal food
- 3.PMID: 37509903 (2023) — Mechanism of Anti-Diabetic Activity from Sweet Potato (Ipomoea batatas): A Systematic Review. · Foods (Basel, Switzerland)
- 4.PMID: 35956541 (2022) — Analysis of Chlorogenic Acid in Sweet Potato Leaf Extracts. · Plants (Basel, Switzerland)
- 5.PMID: 34639164 (2021) — Potential Effects of Sweet Potato (Ipomoea batatas) in Hyperglycemia and Dyslipidemia-A Systematic Review in Diabetic Retinopathy Context.